Wyeth Finally Cleared For Pristiq Lift-Off, But With Lower Dose
Executive Summary
Approval of Wyeth's Pristiq (desvenlafaxine) comes at the lower dose that was submitted late in the review process and with a request for a postmarketing study to determine if even lower doses would be effective
You may also be interested in...
Targacept, AstraZeneca Face Another Failure With NNR Class
The Targacept/AstraZeneca partnership faces another major setback as they decide not to file their neuronal nicotinic receptor modulator TC-5214 in major depressive disorder. Targacept CEO chalks the trial failure up to the gray areas of depression trial design.
Niche, Lackluster: Two Words That Sum Up 2008 NME Launches
The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior
Niche, Lackluster: Two Words That Sum Up 2008 NME Launches
The year 2008 won't go down as the bleakest for new molecular entity drug launches. After all, FDA did approve 24 novel biologics and new molecular entities in 2008, more than in any of the three years prior